人MxA基因重组真核载体抗乙型肝炎病毒作用的实验室研究  

Experimental study of antiviral effects of recombinant eukaryotic plasmid PcDNA3.1-MxA on Hepatitis B virus

作　　者：黄琴[1] 彭明利[2,3] 赵瑞秋[1] 刘爱平[1] 任红[2,3] 许红梅[1] 

机构地区：[1]重庆医科大学儿童医院传染科,重庆400014 [2]重庆医科大学感染性疾病分子生物学教育部重点实验室 [3]重庆医科大学病毒性肝炎研究所,重庆400010

出　　处：《重庆医科大学学报》2010年第1期46-48,共3页Journal of Chongqing Medical University

摘　　要：目的:研究重组真核载体PcDNA3.1-MxA体外抗HBV的作用,为研究MxA基因(myxovirus-resistant A)治疗慢性HBV感染奠定基础。方法:将构建成功的重组真核载体PcDNA3.1-MxA转染入HepG2.2.15。将HepG2.2.15分为实验组(转染PcDNA3.1-MxA的HepG2.2.15)和对照组(转染PcDNA3.1的HepG2.2.15),应用RT-PCR方法检测两组HepG2.2.15内MxA mRNA(P<0.01),并应用ELISA法检测两组HepG2.2.15内HBsAg、HBeAg的水平。结果:RT-PCR扩增结果显示实验组的MxA mRNA水平均较对照组明显升高,实验组HBsAg、HBeAg水平明显低于对照组(均P<0.01)。结论:转染重组真核载体PcDNA3.1-Mx AHepG2.2.15内MxA蛋白明显抑制了HBV DNA的复制及表达,为进一步研究MxA蛋白体内抗病毒作用提供理论。Objective： To investigate the anti-HBV effects of the recombinant eukaryotic plasmid PcDNA3. 1-MxA in HepG 2.2.15 cells in vitro. Methods： The recombinant eukaryotic plasmid PcDNA3.1-MxA was transfected into HepG 2.2.15 cells with Lipofection after extracted and confirmed with restrictive endonuclease analysis. The control group was HepG2.2.15 cells transfected with PcDNA3.1. The levels of MxA mRNA were detected by RT-PCR and the titers of HBsAg and HBeAg in supernatant liquids were detected by ELISA. Results： The RT-PCR results showed the level of MxA mRNA in the treatment group was much higher than that in the control group. The titers of HBsAg and HBeAg in supernatant liquid of the treatment group were significantly lower than those in the control group cells（P〈0.01 ）. Conclusion ： The study indicates that MxA protein can inhibit replication and expression of HBV.

关 键 词：PcDNA3.1-MxA HEPG2.2.15 HBV复制及表达 

分 类 号：R512-3[医药卫生—内科学]